PURPOSE: Mycobacterium bovis bacillus Calmette-Guérin is the most effective treatment for high risk noninvasive bladder cancer. Although bacillus Calmette-Guérin immunotherapy clearly decreases recurrence and progression rates, side effects are common and infection with the bacillus has been described. For these reasons it is necessary to find safer alternatives to the live bacillus. We explored the possibility of using killed but metabolically active bacillus Calmette-Guérin. MATERIALS AND METHODS: T24, J82 and RT4 bladder tumor cell lines were cultured with live and irradiation or heat treated bacillus Calmette-Guérin Connaught. We measured the inhibition of cell proliferation and the production of cytokines in cell culture supernatants. Peripheral mononuclear blood cells were also infected and the production of different cytokines in cell culture supernatants was analyzed. Peripheral blood mononuclear cell and cell culture supernatants activated by mycobacteria were then cultured with T24 cells to analyze whether they showed cytotoxic activity. RESULTS: Compared to the other bacillus Calmette-Guérin treatments, γ irradiated bacillus Calmette-Guérin showed activity similar to that of the live bacillus for inhibiting tumor growth and inducing cytokine production. Irradiated bacillus Calmette-Guérin showed metabolic activity and, thus, was considered killed but metabolically active. This is the treatment that most accurately preserved the mycobacterial structure. Killed but metabolically active bacillus Calmette-Guérin induced cytokine production by infected peripheral mononuclear blood cells. Mycobacteria activated peripheral blood mononuclear cell and cell supernatants showed cytotoxic activity against tumor cells, retaining the antitumor capacity of the live bacillus. CONCLUSIONS: Our results suggest that killed but metabolically active bacillus Calmette-Guérin could be considered a safer immunotherapy alternative to treatment with the live bacillus.
PURPOSE:Mycobacterium bovisbacillus Calmette-Guérin is the most effective treatment for high risk noninvasive bladder cancer. Although bacillus Calmette-Guérin immunotherapy clearly decreases recurrence and progression rates, side effects are common and infection with the bacillus has been described. For these reasons it is necessary to find safer alternatives to the live bacillus. We explored the possibility of using killed but metabolically active bacillus Calmette-Guérin. MATERIALS AND METHODS: T24, J82 and RT4 bladder tumor cell lines were cultured with live and irradiation or heat treated bacillus Calmette-Guérin Connaught. We measured the inhibition of cell proliferation and the production of cytokines in cell culture supernatants. Peripheral mononuclear blood cells were also infected and the production of different cytokines in cell culture supernatants was analyzed. Peripheral blood mononuclear cell and cell culture supernatants activated by mycobacteria were then cultured with T24 cells to analyze whether they showed cytotoxic activity. RESULTS: Compared to the other bacillus Calmette-Guérin treatments, γ irradiated bacillus Calmette-Guérin showed activity similar to that of the live bacillus for inhibiting tumor growth and inducing cytokine production. Irradiated bacillus Calmette-Guérin showed metabolic activity and, thus, was considered killed but metabolically active. This is the treatment that most accurately preserved the mycobacterial structure. Killed but metabolically active bacillus Calmette-Guérin induced cytokine production by infected peripheral mononuclear blood cells. Mycobacteria activated peripheral blood mononuclear cell and cell supernatants showed cytotoxic activity against tumor cells, retaining the antitumor capacity of the live bacillus. CONCLUSIONS: Our results suggest that killed but metabolically active bacillus Calmette-Guérin could be considered a safer immunotherapy alternative to treatment with the live bacillus.
Authors: Mirela Kremenovic; Alfred A Chan; Bing Feng; Lukas Bäriswyl; Steve Robatel; Thomas Gruber; Li Tang; Delphine J Lee; Mirjam Schenk Journal: J Immunother Cancer Date: 2022-06 Impact factor: 12.469
Authors: Periela da Silva Sousa-Vasconcelos; Wellington da Silva Seguins; Eduardo de Souza Luz; Rosa Teixeira de Pinho Journal: Mem Inst Oswaldo Cruz Date: 2015-09 Impact factor: 2.743
Authors: Aseem Pandey; Ana Cabello; Lavoisier Akoolo; Allison Rice-Ficht; Angela Arenas-Gamboa; David McMurray; Thomas A Ficht; Paul de Figueiredo Journal: PLoS Negl Trop Dis Date: 2016-08-18
Authors: Nuria Andreu; Jody Phelan; Paola F de Sessions; Jacqueline M Cliff; Taane G Clark; Martin L Hibberd Journal: Sci Rep Date: 2017-02-08 Impact factor: 4.379
Authors: Thomas E Bickett; Jennifer McLean; Elizabeth Creissen; Linda Izzo; Cassidy Hagan; Antonio J Izzo; Fabiola Silva Angulo; Angelo A Izzo Journal: Front Immunol Date: 2020-06-18 Impact factor: 7.561
Authors: Jelmer H van Puffelen; Samuel T Keating; Egbert Oosterwijk; Antoine G van der Heijden; Mihai G Netea; Leo A B Joosten; Sita H Vermeulen Journal: Nat Rev Urol Date: 2020-07-16 Impact factor: 14.432